A phase i/ii study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

HIGHLIGHTS

• who: Aaron S. Mansfield from the Published in partnership with The Hormel Institute, University of Minnesota have published the paper: A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors, in the Journal: (JOURNAL) of October/14,/2019
• what: Given the activity of Rova-T observed in studies of SCLC and the prevalence of DLL3 expression in solid tumors described above, this study examined the safety, tolerability, and antitumor activity of Rova-T in patients with DLL3-positive tumors, including NEC/ NET, melanoma, MTC, GBM, and other solid tumors . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.